What is RETATRUTIDE 30mg
Retatrutide is a next-generation incretin-based research compound investigated as a triple agonist (GLP-1/GIP/glucagon receptors) for its effects on energy balance, glycemic control, and body-composition signaling in controlled laboratory models.
Potential Research Effects
• Appetite regulation and energy-expenditure pathway studies
• Glucose control and insulin-sensitivity modeling (incretin signaling)
• Lipid metabolism and adiposity reduction research
• Body-composition and weight-management paradigms
• Hepatic and peripheral metabolic regulation exploration
Includes 10 sterile research-use syringes with every vial order.
Cybergen Peptides: Research Use Disclaimer
All products offered by Cybergen Peptides are intended solely for laboratory, educational, and scientific research purposes.
These materials are supplied for in-vitro research only (“in glass”) and are
not intended for human or animal consumption, medical use, or diagnostic applications.
Cybergen Peptides compounds are not drugs, medicines, or dietary supplements and have
not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
They are not intended to diagnose, treat, cure, or prevent any disease.
Any form of bodily introduction, clinical testing, or therapeutic application is strictly prohibited.
